INT8067

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.25
First Reported 1992
Last Reported 2011
Negated 1
Speculated 0
Reported most in Body
Documents 12
Total Number 13
Disease Relevance 10.33
Pain Relevance 1.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (AGT) small molecule metabolic process (AGT) aging (AGT)
extracellular region (AGT) extracellular matrix organization (AGT) cell-cell signaling (AGT)
Anatomy Link Frequency
brain 2
AGT (Homo sapiens)
Pain Link Frequency Relevance Heat
bradykinin 74 97.68 Very High Very High Very High
Angina 8 97.60 Very High Very High Very High
Glutamate 9 96.36 Very High Very High Very High
fibrosis 7 95.56 Very High Very High Very High
beta blocker 18 94.80 High High
Inflammation 27 92.36 High High
peptic ulcer disease 15 89.12 High High
Pain 4 87.20 High High
antagonist 30 85.68 High High
narcan 1 78.48 Quite High
Disease Link Frequency Relevance Heat
Diabetes Mellitus 296 99.82 Very High Very High Very High
Hypertension 262 98.80 Very High Very High Very High
Syndrome 96 98.72 Very High Very High Very High
Cv General 3 Under Development 11 97.60 Very High Very High Very High
Drug Induced Neurotoxicity 9 96.92 Very High Very High Very High
Myocardial Infarction 72 96.80 Very High Very High Very High
Internal Fibrosis 2 95.56 Very High Very High Very High
Ulcers 14 94.00 High High
Diabetic Retinopathy 54 93.72 High High
Vasculitis 4 92.36 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Pharmacological agents such as ACE inhibitors, that actively prevent the formation of angiotensin II, may therefore have a beneficial effect in terms of end-organ protection beyond their activity on BP.
Negative_regulation (prevent) of angiotensin II Neg (prevent) Binding (formation) of
1) Confidence 0.25 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994025 Disease Relevance 0.63 Pain Relevance 0
Oral treatment with angiotensin-converting enzyme inhibitors, which interfere with the formation of angiotensin II, prevents the development of hypertension in young SHR by acting, at least in part, upon the brain RAS.
Negative_regulation (interfere) of angiotensin II Binding (formation) of in brain associated with hypertension
2) Confidence 0.13 Published 1992 Journal Brain Res. Brain Res. Rev. Section Abstract Doc Link 1361394 Disease Relevance 0.55 Pain Relevance 0.17
They suggested that the reparative functions of the mucous of the gastrointestinal track were influenced by a reduction of angiotensin II formation and activation of the renin-kallicrein-kinin system.
Negative_regulation (reduction) of angiotensin II Binding (formation) of
3) Confidence 0.11 Published 2008 Journal BMC Endocr Disord Section Body Doc Link PMC2632632 Disease Relevance 1.52 Pain Relevance 0.21
Therefore, blocking the generation of angiotensin-II or inhibiting its binding to specific receptors may decrease the subsequent risk for unstable angina and acute myocardial infarction.
Negative_regulation (inhibiting) of angiotensin-II Binding (binding) of associated with angina and myocardial infarction
4) Confidence 0.10 Published 2000 Journal Curr. Opin. Cardiol. Section Abstract Doc Link 10952419 Disease Relevance 0.69 Pain Relevance 0.10
In experimental diabetic models, inhibition of angiotensin II formation with ACE inhibition results in suppression of VEGF expression (Moravski et al 2000; Higgins et al 2003).
Negative_regulation (inhibition) of angiotensin II Binding (formation) of associated with diabetes mellitus
5) Confidence 0.05 Published 2007 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2701139 Disease Relevance 1.26 Pain Relevance 0
ACE inhibitors blocked the liberation of angiotensin II from angiotensin I.
Negative_regulation (blocked) of angiotensin II Binding (liberation) of
6) Confidence 0.05 Published 2007 Journal Clinical ophthalmology (Auckland, N.Z.) Section Abstract Doc Link PMC2701139 Disease Relevance 0.89 Pain Relevance 0.19
In experimental diabetic models, inhibition of angiotensin II formation with ACE inhibition results in suppression of VEGF expression (Moravski et al 2000; Higgins et al 2003).
Negative_regulation (inhibition) of angiotensin II Binding (formation) of associated with diabetes mellitus
7) Confidence 0.05 Published 2007 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2701139 Disease Relevance 1.26 Pain Relevance 0
Although ACE inhibitors are able to reduce angiotensin II formation, non-ACE dependent pathways have also been identified.137 On the other hand, ARBs antagonize the binding of angiotensin II to the AT1 receptor, which mediates most of the undesirable effects associated with angiotensin II.
Negative_regulation (reduce) of angiotensin Binding (binding) of
8) Confidence 0.05 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2686259 Disease Relevance 0.66 Pain Relevance 0.09
Although ACE inhibitors are able to reduce angiotensin II formation, non-ACE dependent pathways have also been identified.137 On the other hand, ARBs antagonize the binding of angiotensin II to the AT1 receptor, which mediates most of the undesirable effects associated with angiotensin II.
Negative_regulation (reduce) of angiotensin Binding (formation) of
9) Confidence 0.05 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2686259 Disease Relevance 0.63 Pain Relevance 0.09
As RAAS has been implicated in oxidative damage, its interruption though ACE inhibition or angiotensin blockade may prevent the development of CRS.
Negative_regulation (blockade) of angiotensin Binding (interruption) of associated with syndrome
10) Confidence 0.04 Published 2011 Journal International Journal of Nephrology Section Body Doc Link PMC2989717 Disease Relevance 0.89 Pain Relevance 0.15
As RAAS has been implicated in oxidative damage, its interruption though ACE inhibition or angiotensin blockade may prevent the development of CRS.
Negative_regulation (inhibition) of angiotensin Binding (interruption) of associated with syndrome
11) Confidence 0.04 Published 2011 Journal International Journal of Nephrology Section Body Doc Link PMC2989717 Disease Relevance 0.89 Pain Relevance 0.15
Valsartan is a specific blocker of the binding of angiotensin II to the AT1 receptor, blocking the vasoconstrictor effect and the adrenal aldosterone secretion induced by this peptide.
Negative_regulation (blocker) of angiotensin Binding (binding) of
12) Confidence 0.04 Published 2010 Journal Core evidence Section Body Doc Link PMC2899780 Disease Relevance 0.48 Pain Relevance 0.18
With either DRI combination, PRA is suppressed and formation of angiotensin I is greatly reduced, thus providing less substrate to drive escape pathways.


Negative_regulation (reduced) of angiotensin I Binding (formation) of
13) Confidence 0.03 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941784 Disease Relevance 0 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox